Some thoughts; Altria got one director on the Lexaria board now, they will have another 2, if they continue and pay Lexaria (11 millions I think)for the rights to use the formula. This decision shall be taken within 2020 by Altria. IF they do... 11 million dollars is a lot, even for Altria. Then one can be pretty sure (?) they are commited to follow up with recent product development and a clear path to market with new products. The fact they then will have 3 directors on the board, also give them significant increasing influence. Lexaria should then; 1. get 11 million dollars, 2,license fees and 3.royalty percentage of Altrias sales. Possible FIRST catalysator, within this year. To have a new signed deal and active continued collaboration, could be a key to strengthen and close now potential further agreements within the 4-division-strategy. (Could possibly also give more credit to get Lexarias approval on Nasdaq application)

Read More: https://investorshangout.com/messages/view?id...z6YX1e5Us3